Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med

Novo Nordisk ($NVO) is humming along with its fast-growing GLP-1 drug Victoza. But it's also eyeing a follow-up to that once-daily med, touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that the drug slashed HbA1c levels and delivered significant weight loss in a new trial. More data is coming later this year. Report | Release